Buy SNAP-8

SNAP-8 is a synthetic analog of the N-terminal fragment of SNAP-25, a protein essential for the SNARE complex that mediates neurotransmitter (acetylcholine) vesicle fusion at the neuromuscular junction. By competing with SNAP-25, SNAP-8 partially inhibits vesicle fusion and reduces acetylcholine release — relaxing muscle contraction.

Reduced muscle contraction at facial expression points (glabella, forehead, crow's feet, nasolabial fold) decreases the mechanical stress that deepens expression lines over time. Applied topically in cosmetic formulations, SNAP-8 provides a non-injectable analog to botulinum toxin's mechanism.

SNAP-8 is a synthetic octapeptide (8 amino acids) developed by Lipotec. It is an analog of the N-terminal end of SNAP-25, a protein involved in acetylcholine vesicle release at neuromuscular junctions. By partially inhibiting SNAP-25, it reduces muscle contraction and the formation of expression lines.

SNAP-8 works through the same mechanistic pathway as botulinum toxin — reducing acetylcholine release at the neuromuscular junction. However, it is a peptide applied topically rather than a bacterial toxin injected directly into muscle. Its effect is partial and reversible, making it a lower-intensity alternative for research on expression line reduction.

Argireline is a hexapeptide (Acetyl Hexapeptide-3); SNAP-8 is the octapeptide extension of the same SNARE-inhibition concept. The additional two amino acids in SNAP-8 produce tighter SNAP-25 analog binding and, in published cosmetic studies, roughly 30% greater wrinkle depth reduction than Argireline at the same concentration over a 28-day topical protocol.

Published dermal research typically uses 5–10% SNAP-8 in a suitable carrier (usually glycerol or propylene glycol based). The Lipotec benchmark studies used a 10% concentration over 28–56 days. Higher concentrations have not shown meaningfully greater expression-line reduction in comparative protocols.

SNAP-8 targets expression wrinkles (muscle-driven) while compounds like GHK-Cu target collagen structure and dermal remodeling. The two mechanisms don't compete — published dermal research commonly pairs them in split-formulation protocols where SNAP-8 addresses dynamic lines and GHK-Cu addresses static wrinkles and skin tone.

SNAP-8 was engineered for topical delivery. Subcutaneous administration is not supported by published research — the octapeptide structure is optimized for stratum corneum penetration and local neuromuscular junction effects, not systemic circulation. Injection protocols are outside the compound's documented mechanism.